Europe — EMA
Granisetron Ratiopharm
Granisetron Ratiopharm is an oral 5‑HT3 antagonist used to prevent chemotherapy‑ and postoperative‑induced nausea and vomiting. Learn indications, safety and dosing.
Request sourcing
What is Granisetron?
Granisetron Ratiopharm is an oral medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist. It is marketed in the European Union as a prescription product and is formulated for oral administration. The drug works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract, helping to prevent nausea and vomiting associated with chemotherapy and surgery and postoperative recovery in patients.
What is Granisetron used for?
Granisetron Ratiopharm is indicated for the prevention of nausea and vomiting in specific clinical settings.
- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures. - Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated. - Management of nausea associated with radiotherapy in patients receiving moderate to high dose treatments. - Adjunct therapy for nausea related to other serotonergic triggers when clinically appropriate.
What are the side effects of Granisetron?
The safety profile of Granisetron Ratiopharm includes a range of observed adverse events, most of which are mild and transient.
Common: - Headache - Constipation or mild abdominal discomfort - Dizziness or light‑headed feeling - Fatigue
Serious: - Severe allergic reaction (anaphylaxis, rash, swelling) - Cardiac arrhythmias or QT interval prolongation - Persistent severe constipation leading to bowel obstruction
What precautions apply to Granisetron?
Before prescribing Granisetron Ratiopharm, clinicians should evaluate patient history and consider several precautionary factors to minimize risk.
- Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use cautiously in patients with a history of cardiac conduction disorders or prolonged QT interval. - Evaluate renal and hepatic function, as dose adjustments may be needed in severe impairment. - Monitor for signs of severe constipation, especially in patients with gastrointestinal motility disorders. - Consider pregnancy and breastfeeding status; safety data are limited. - Review concomitant medications that may affect cardiac rhythm.
What does Granisetron interact with?
Granisetron Ratiopharm can interact with other drugs, and certain combinations should be avoided or used with careful monitoring.
Avoid: - Other medications known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics). - Strong CYP3A4 inhibitors that may increase granisetron plasma levels (e.g., ketoconazole, itraconazole).
Use with caution: - Drugs that affect cardiac conduction (e.g., digoxin, certain anti‑emetics). - Medications that may cause additive constipation (e.g., opioids, anticholinergics). - Concurrent use of other serotonergic agents, monitoring for serotonin syndrome.
